HopeStage
Back to all studies
CompletedNCT00254748

The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A study

It tested quetiapine fumarate for Borderline Personality Disorder.

Personality disorders, Borderline personalityDrugFrom 18 Years to 55 Years
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
Apeldoorn, Netherlands · Nijmegen, Netherlands and 1 more locationSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study information

Study start dateJune 2004
Recruitment status
Completed
Enrollment listed in the registry
40
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Netherlands
Age range
From 18 Years to 55 Years
Official registry ID
NCT00254748
Official title
The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Apeldoorn · Nijmegen · Veghel

Registry details
Registry conditions (original wording)

Borderline Personality Disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine fumarate and Placebo.

Who was this study for?

Listed age limits: 18 years to 55 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me